2024REPORTING News & Analysis

Impressive full year results lifted the neobank's valuation even higher. The rally may be overdone.

Investors cheer the latest results as the distribution is lifted 6%. 

An enviable brand but supplier problems have derailed the shares which remain undervalued.

We reaffirm our full year guidance and the firm remains undervalued.

Our view after the shares have appreciated over 42% in the last year. 

We heard from some of the heavy weights in the ASX 200 including CBA and CSL.

We leave our fair value unchanged but the shares are trading at a 11% discount.

Our analysts disagree with how the market is valuing these ASX companies. Next week’s earnings reports could offer some clues as to whether we...

Has the share price run too far or is there room for further gains?

Pro Medicus reported another strong set of results. It continues to trade at a lofty valuation.